Loading...

WANBURY Wanbury Ltd Product Launches Announcement

Wnbr

WNBR

Wanbury Ltd

(WANBURY)

2024 Announcement

Show Summary

Show Summary

Annual Compliance Report

Q4 FY25 Results

GMP Certification

Management Changes

Certification Achieved

SAP Implementation

Regulatory Compliance

Improved Capacity

Investor Plant Visit

New Product Launches

Debt Refinancing Success

Debenture Allotment

New Directors Appointed

Management Changes

Management Changes

Q3 FY25 Results

Fundraising Announcement

Management Appointment

EGM Announcement

EGM Announcement

New Directors Appointed

Director Appointments

Management Change

Compliance Certificate

ANVISA Audit Success

Successful ANVISA Inspection

Investor Meeting

Investor Meet Scheduled

Management Change

Management Change

Q2 FY25 Results

Dematerialization Compliance

Management Changes

Auditor Appointment

Management Changes

API Product Update

New Product Approval

Annual General Meeting

AGM Announcement

FDA Inspection Update

Safety Awards Won

Q1 FY25 Results

CEO Appointment

CEO Appointment

Director Appointment

Auditor Appointment

Management Appointment

Auditor Resignation

Management Changes

Certificate Submission

Loan Disbursement

Analyst/Investor Meeting

US FDA Inspection Announcement

Successful FDA Inspection

Compliance Report Submission

Financial Results

Financial Results

Certificate Submission

Investor Meeting Scheduled

Compliance Certificate

Regulatory Compliance

Management Change

Analyst/Investor Meet

Management Change

Change in Management

Change in Management

Financial Results Announcement

Certificate Submission

Change in VWAP Calculation ...

Management Appointment

Advertisement Publication

Certificate Submission

AGM Announcement

Debt-Equity Swaps

Management Changes

Management Changes

Financial Statements

Board Meeting Rescheduled

Board Meeting for Financial...

Regular Earnings Release

Result Announcement

Annual Compliance Report

Board Meeting Postponed

External Links:

Data:

Wanbury Limited has received a Certificate of Suitability (CEP) for its Dextromethorphan active pharmaceutical ingredient, enabling it to commence commercial sales in European markets; the global market for this product is valued at USD 2,500 million

AI Assistant

Wanbury Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.